COLL250117P22500
- 0.60
- 0.000.00%
Collegium Pharmaceutical Newsroom
Jefferies Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $40
H.C. Wainwright Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $50
Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Collegium Pharmaceutical (COLL)
Needham Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating
Piper Sandler Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating, Maintains Target Price $37
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Collegium Pharmaceutical (COLL) and Korro Bio (KRRO)
Piper Sandler Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating, Maintains Target Price $37
Collegium Pharmaceutical Analyst Ratings
H.C. Wainwright Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Raises Target Price to $50
Collegium Pharmaceutical Price Target Cut to $37.00/Share From $39.00 by Piper Sandler
Collegium Pharmaceutical Analyst Ratings
Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating
H.C. Wainwright Upgrades Collegium Pharmaceutical(COLL.US) to Buy Rating, Announces Target Price $47
Collegium Pharmaceutical Analyst Ratings
Needham Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating
Collegium Pharmaceutical Analyst Ratings
Jefferies Upgrades Collegium to Buy, Cites Upside Related to LOEs
Collegium Downgraded by Piper Sandler Over Valuation